OT:
Dok, from the investors pres on the website, they are targeting markets totaling $43b, of which migraines are 4.6b. They are approved for $20b of markets (migraines + chronic pain), and are launching right now.
The issue with this one is the abuse potential; pain reliever addiction is a major issue. The issue in front of the company is that many states are looking to ban it due to these addiction issues.
I've been following this one a bit. The charts suggest last week may have been a bottom.